Evaluation of tadalafil for the treatment of erectile dysfunction
Abstract
Tadalafil is an oral phosphodiesterase type-5 inhibitor for male erectile dysfunction (ED). It has been proved to improve erectile function, with safety and effectiveness lasting up to 36 h, allowing patients to choose when to have sexual activities. Tadalafil is also efficacious in the treatment of ED associated with such diseases as hypertension, diabetes mellitus, etc. This article reviews the available evidence for the efficacy of tadalafil on ED and related diseases.
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
- Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent
- Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review
- Molecular Docking of Silymarin as a Ligand for Aromatase Enzyme and HIV-1 Reverse Transcriptase Using Molegro Virtual Docker
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.